Patent search ap:"LEAD DISCOVERY CENTER GMBH" Page 1

1.

发明申请
MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS 有权

公开(公告)号：US20240415819A1

公开(公告)日：2024-12-19

申请号：US18694432

申请日：2022-09-25

Applicant: Lead Discovery Center GmbH , QLI5 THERAPEUTICS AG

Inventor： Uwe Koch , Gunther Zischinsky , Anke Unger , Peter Nussbaumer , Bert Klebl , Axel Choidas , Klaus Dinkel , Julian Engel , Carsten Degenhart , Robert Huber , Kiyean Nam , Jaesung Kim , Jeongjea Seo , Seung-Joo Lee , Yeejin Jeon , Wongyun Ahn

IPC: A61K31/439 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K31/5386 , A61P35/00 , C07D498/08 , C07D519/00

Abstract: The present invention relates to certain macrocyclic compounds of the formula (I) and pharmaceutically acceptable salts thereof. These compounds are useful in the treatment or prevention of a disease associated with and/or caused by proteasome or immunoproteasome, selected from a cancer, an infectious disease, an inflammatory disease, and autoimmune disease.

2.

发明授权
Inhibitors of glucose transporters (GLUTs) 有权

公开(公告)号：US12060362B2

公开(公告)日：2024-08-13

申请号：US17273549

申请日：2019-09-05

Applicant: LEAD DISCOVERY CENTER GMBH , MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.

Inventor： Herbert Waldmann , Gunther Zischinsky , Peter Nussbaumer , Slava Ziegler , Melanie Schwalfenberg , Javier de Ceballos Cerrajeria , Elena Sabrina Reckzeh , George Karageorgis

IPC: C07D491/08 , A61K31/529

CPC classification number: C07D491/08

Abstract: The present invention relates to 2,6-methanobenzo[g][1]oxacin-4-one compounds and their analog compounds and pharmaceutically acceptable salts thereof as selective inhibitor of glucose transporters 1 and 3 (GLUTs 1 and 3), to methods of preparing said compounds, and to the use thereof as pharmaceutically active agents, especially for the prophylaxis and/or treatment of metabolic diseases, immunological diseases, autoimmune diseases, inflammation, graft versus host disease, cancer, and metastasis thereof. Furthermore, the present invention is directed to pharmaceutical composition comprising at least one of 2,6-methanobenzo[g][1]oxacin-4-one compounds and their analog compounds.

3.

发明申请
QUINOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER 有权

公开(公告)号：US20220169616A1

公开(公告)日：2022-06-02

申请号：US17440468

申请日：2020-03-19

Applicant: Lead Discovery Center GmbH

Inventor： Raffaella Di Lucrezia , Tim Bergbrede , Peter Nussbaumer , Peter Schröder

IPC: C07D215/20 , A61K31/47 , C07D401/12 , A61K31/4709 , A61K31/4375 , C07D471/04 , C07D471/10 , A61K31/438 , A61K45/06 , A61P35/00 , C07D491/107 , A61K31/5377 , C07D519/00

Abstract: The present invention relates to compounds of the general formula (I): (I), wherein V, W, M, R, R and Y have the designations cited below, or a pharmaceutically or veterinary acceptable salt, hydrate or solvate thereof, and to processes for the preparation of compounds of the general formula (I) or a pharmaceutically or veterinary acceptable salt, hydrate or solvate thereof. The invention also relates to compounds of the general formula (I) or a pharmaceutically or veterinary acceptable salt, hydrate or solvate thereof for use as a medicament. Further, the invention relates to compounds of the general formula (I) or a pharmaceutically or veterinary acceptable salt, hydrate or solvate thereof for use in the treatment of cancer. Moreover, the invention relates to compounds of the general formula (I) or a pharmaceutically or veterinary acceptable salt, hydrate or solvate thereof for treating cancer in simultaneous, alternating or subsequent combination with another cancer therapy.

4.

发明申请
PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES 有权

公开(公告)号：US20220098208A1

公开(公告)日：2022-03-31

申请号：US17548978

申请日：2021-12-13

Applicant: QURIENT CO., LTD. , LEAD DISCOVERY CENTER GMBH

Inventor： KIYEAN NAM , JAESEUNG KIM , YEEJIN JEON , DONGHOON YU , MOOYOUNG SEO , DONGSIK PARK , JAN EICKHOFF , GUNTHER ZISCHINSKY , UWE KOCH

IPC: C07D487/04 , C07D519/00

Abstract: The present invention relates to pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.

5.

发明申请
COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER 审中-公开

公开(公告)号：US20200291011A1

公开(公告)日：2020-09-17

申请号：US16648348

申请日：2018-09-20

Applicant: Lead Discovery Center GmbH , Max Planck Gesellschaft zur Förderung der Wissenschften e.V. , SOTIO a.s.

Inventor： Raffaella Di Lucrezia , Tim Bergbrede , Peter Nussbaumer , Uwe Koch , Bert Klebl , Axel Choidas , Anke Unger , Nils-Göran Larsson , Maria Falkenberg-Gustafsson , Claes M. Gustafsson

IPC: C07D413/14 , C07D405/12 , C07D311/18 , C07D491/052 , C07D409/14 , C07D409/04

Abstract: The invention provides novel coumarin derivatives as specific mitochondrial RNA polymerase inhibitors for the treatment of cancer.

6.

发明申请
4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER 审中-公开

公开(公告)号：US20200031794A1

公开(公告)日：2020-01-30

申请号：US16519856

申请日：2019-07-23

Applicant: Lead Discovery Center GmbH , Max Planck Gesellschaft zur Förderung der Wissenschaften e. V.

Inventor： Raffaella Di Lucrezia , Tim Bergbrede , Peter Nussbaumer , Uwe Koch , Bert Klebl , Axel Choidas , Anke Unger , Nils-Göran Larsson , Maria Falkenberg-Gustafsson , Claes M. Gustafsson

IPC: C07D311/54 , C07D407/12 , C07D407/14 , C07D413/12

Abstract: The invention provides novel 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof as specific mitochondrial RNA polymerase inhibitors for the treatment of cancer.

7.

发明公开
COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION 审中-公开

公开(公告)号：US20240252454A1

公开(公告)日：2024-08-01

申请号：US18289283

申请日：2022-05-02

Applicant: LEAD DISCOVERY CENTER GMBH , MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.

Inventor： Tim BERGBREDE , Raffaella DI LUCREZIA , Anke UNGER , Axel CHOIDAS , Bert KLEBL , Peter NUSSBAUMER , Sascha MENNINGER , Peter HABENBERGER , Gunther ZISCHINSKY , Uwe KOCH , Peter SCHRÖDER , Pavla JESTRABOVÁ , Lenka PALOVÁ-JELÍNKOVÁ , Klára DÁNOVÁ , Maria FALKENBERG-GUSTAFSSON , Laleh ARABANIAN , Claes GUSTAFSSON , Nils-Göran LARSSON , Lars PALMQVIST

IPC: A61K31/166 , A61K31/4184 , A61K31/453 , A61K31/47 , A61K31/496 , A61K31/5377 , A61K31/711 , A61P35/00

CPC classification number: A61K31/166 , A61K31/4184 , A61K31/453 , A61K31/47 , A61K31/496 , A61K31/5377 , A61K31/711 , A61P35/00

Abstract: The present invention relates to a composition comprising at least one inhibitor of mitochondrial transcription (IMT) and at least one anti-cancer drug. Furthermore, the present invention is directed to compositions for use as a medicament and to compositions for use in the treatment and/or prevention of cancer.

8.

发明授权
Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors 有权

公开(公告)号：US11858937B2

公开(公告)日：2024-01-02

申请号：US17045009

申请日：2019-04-11

Applicant: QURIENT CO., LTD. , LEAD DISCOVERY CENTER GMBH

Inventor： Kiyean Nam , Jaeseung Kim , Yeejin Jeon , Donghoon Yu , Mooyoung Seo , Dongsik Park , Jan Eickhoff , Gunther Zischinsky , Uwe Koch

IPC: A61K31/519 , A61K31/53 , C07D487/04

CPC classification number: C07D487/04

Abstract: The present invention relates to pyrazolo [1,5-a][1,3,5]triazine and pyrazolo [1,5-a]pyrimidine derivatives having Formula I:

and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.

9.

发明申请
4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER 有权

公开(公告)号：US20220370440A1

公开(公告)日：2022-11-24

申请号：US17270221

申请日：2019-08-23

Applicant: Lead Discovery Center GmbH

Inventor： Carsten Schultz-Fademrecht , Bert Klebl , Peter Nussbaumer , Carsten Degenhart , Matthias Baumann

IPC: A61K31/496 , A61K45/06 , C07D471/04 , A61K31/4545 , A61K31/437 , A61K31/5377 , A61K31/506 , A61K31/538 , A61K31/4709

Abstract: The present invention relates to certain 4-substituted 1H-pyrrolo[2,3-b]pyridine compounds of the formula (I) and pharmaceutically acceptable salts thereof. These compounds is useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of ErbB receptor, especially of Exon20 Her2 and EGFR mutations.